摘要
目的观察两种剂量复方甘草酸苷片(美能)治疗慢性乙型肝炎的疗效和安全性。方法60例慢性乙型肝炎患者随机分为A组(30例)和B组(30例),始初每月静脉滴注美能注射液80 mL,共4周。后改美能片口服,A组3次/d,每次2片;B组3次/d,每次3片,共24周。观察两组的疗效和不良反应。结果治疗结束后,两组显效率和有效率分别为73.3%(22/30)、16.7%(5/30)和76.7%(23/30)、20.0%(6/30),差异无统计学意义(P>0.05)。两组ALT、AST正常率分别为60.0%(18/30)、56.7%(17/30)和66.7%(20/30)、60.0%(18/30),差异无统计学意义(P>0.05)。治疗前后血电解质钠和钾水平无明显变化(P>0.05),偶发轻度药物不良反应,可自行缓解,不需停药。结论美能片能显著降低慢性乙型肝炎患者的ALT水平,美能6片与9片的降酶疗效相仿,长期服用可有效治疗慢性乙肝并提高患者的生活质量,仅偶发轻微副作用,值得推广应用。
Objective To observe the efficacy and safety of oral long-term Stronger Neo-Minophagen C （SNMC） Tablet in pa- tients with chronic hepatitis B. Methods Sixty patients were divided randomly into Group A （30 patients） and Group B （30 patients）, patients were treated with 80 mL of SNMC dissolved in 250 mL 5% gluscose once daily by intravenous drip for 4 weeks. Thereafter, patients in Group A and Group B received daily 2 or 3 tablets of SNMC tab three times a day for an ad- ditional 24 weeks. Results At the end of treatment, marked and substantial response were 73.3%, 16.7% vs 76.7%, 20.0% in Group A and Group B, respectively （P 〉 0.05）. Normalization rate of ALT （〈55 IU/L） was accomplished in 18 （60.0%） and 20 （66.7%） patients in Group A and Group B, respectively （P 〉 0.05）. Minor side-effects occured in paitents but they dit not required any therapies. Conclusion Based on these, SNMC is safe and efficacious in lowering or normalizing ALT levels in patients with chronic hepatitis B. Taken along with infrequent and very mild side effects, long-term oral SNMC would benefit patients with chronic hepatitis B by maintaining their quality of life with easier compliance, so SNMC is wor- thy of clinical promotion and applicatin.
出处
《中国现代医生》
2012年第14期57-59,共3页
China Modern Doctor
基金
浙江省乐清市2011年度社会发展(医学部分)项目(2011Y024)
